Thomas Severin
Overview
Explore the profile of Thomas Severin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1094
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pagnesi M, Staal L, Ter Maaten J, Beldhuis I, Cotter G, Davison B, et al.
JACC Heart Fail
. 2024 Nov;
13(3):414-429.
PMID: 39614837
Background: The prognostic importance of residual congestion after acute heart failure (AHF) hospitalization is still debated. Objectives: The authors aimed to assess the impact of residual congestion in a large...
2.
Takahashi H, Fukunaga A, Hayama K, Sasajima T, Fujishige A, Ichishita R, et al.
Allergol Int
. 2024 Sep;
74(1):136-143.
PMID: 39327219
Background: In Japan, urticaria is a common skin disorder with chronic spontaneous urticaria (CSU) being the most frequent subtype. This study evaluated the safety of ligelizumab (anti-IgE monoclonal antibody) in...
3.
Inciardi R, Staal L, Davison B, Lombardi C, Postmus D, Felker M, et al.
Eur J Heart Fail
. 2024 Sep;
26(11):2431-2439.
PMID: 39240040
Aims: Acute heart failure (AHF) is a major cause of hospitalizations and death in the elderly. However, elderly patients are often underrepresented in randomized clinical trials. We analysed the impact...
4.
Maurer M, Ensina L, Gimenez-Arnau A, Sussman G, Hide M, Saini S, et al.
Lancet
. 2023 Nov;
403(10422):147-159.
PMID: 38008109
Background: Many patients with chronic spontaneous urticaria (CSU) do not achieve complete control of their symptoms with current available treatments. In a dose-finding phase 2b study, ligelizumab improved urticaria symptoms...
5.
Staubach P, Alvaro-Lozano M, Sekerel B, Maurer M, Ben-Shoshan M, Porter M, et al.
Pediatr Allergy Immunol
. 2023 Jul;
34(7):e13982.
PMID: 37492920
Background: Chronic spontaneous urticaria (CSU), a long-lasting disease in children, impacts their quality of life. We report the results of a phase 2b dose-finding trial of ligelizumab (NCT03437278) and a...
6.
Bernstein J, Gimenez-Arnau A, Maurer M, Staubach P, Barbier N, Hua E, et al.
J Clin Med
. 2023 May;
12(10).
PMID: 37240667
This study investigated the association between urticaria activity and health-related quality of life (HRQoL). Patient evaluations from the ligelizumab Phase 2b clinical trial (N = 382) were pooled (NCT02477332). Daily...
7.
Pagnesi M, Adamo M, Ter Maaten J, Beldhuis I, Cotter G, Davison B, et al.
Eur J Heart Fail
. 2023 Mar;
25(4):541-552.
PMID: 36915227
Aims: The impact of mitral regurgitation (MR) in patients hospitalized for acute heart failure (AHF) is not well established. We assessed the role of MR in patients enrolled in the...
8.
Metz M, Bernstein J, Gimenez-Arnau A, Hide M, Maurer M, Sitz K, et al.
World Allergy Organ J
. 2022 Nov;
15(11):100716.
PMID: 36440464
Background: Disease burden is particularly high in Chronic Spontaneous Urticaria (CSU) patients with angioedema, and patients whose signs and symptoms are inadequately controlled by H-antihistamines need new treatment options. Here...
9.
Benito-Villalvilla C, de la Rocha-Munoz A, Lopez-Abente J, Eggel A, Bottoli I, Severin T, et al.
Allergy
. 2022 Oct;
78(4):1060-1072.
PMID: 36315052
Background: Ligelizumab is an anti-IgE monoclonal antibody binding IgE with higher affinity than omalizumab that is under clinical investigation for several IgE-mediated diseases. We previously showed that omalizumab removes IgE...
10.
Pivneva I, Balp M, Geissbuhler Y, Severin T, Smeets S, Signorovitch J, et al.
Dermatol Ther (Heidelb)
. 2022 Oct;
12(12):2747-2763.
PMID: 36301485
Introduction: The time required to reach clinical remission varies in patients with chronic urticaria (CU). The objective of this study is to develop a predictive model using a machine learning...